Products - Blood and bone marrow cancers | Topic | NICE

Showing 67 products

Date | Title

New and updated: New in the last 6 monthsRemove ‘New and updated: New in the last 6 months’ filter

Acalabrutinib and venetoclax with or without obinutuzumab for untreated chronic lymphocytic leukaemia [ID6232]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
7 May 2026
Acalabrutinib with bendamustine and rituximab for untreated mantle cell lymphoma [ID6155]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
22 April 2026
Acalabrutinib with R-CHOP for untreated non-germinal centre B-cell diffuse large B-cell lymphoma [ID6614]
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Axatilimab for treating active chronic graft-versus-host disease after 2 or more systemic treatments in people 2 years and over [ID6570]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Belantamab mafodotin with bortezomib and dexamethasone for treating relapsed or refractory multiple myeloma after 1 or more treatments [ID6212]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
8 April 2026
Belantamab mafodotin with pomalidomide and dexamethasone for previously treated multiple myeloma [ID6211]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
26 February 2026
Brexucabtagene autoleucel for treating relapsed or refractory mantle cell lymphoma after 2 or more systemic treatments (review of TA677) [ID6325]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
11 February 2026
Daratumumab for treating high-risk smouldering multiple myeloma [ID6214]
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Daratumumab with bortezomib, lenalidomide and dexamethasone for untreated multiple myeloma when an autologous stem cell transplant is suitable [ID6249]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
13 May 2026
Daratumumab with bortezomib, lenalidomide and dexamethasone for untreated multiple myeloma when a stem cell transplant is unsuitable [ID3843]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
13 May 2026
Decitabine–cedazuridine with venetoclax for treating acute myeloid leukaemia when intensive induction chemotherapy is unsuitable [ID6601]
Status:
In development | In consultation
Programme:
Technology appraisal guidance
Consultation end date:
11 February 2026
Expected publication date:
TBC
Elranatamab for treating relapsed or refractory multiple myeloma after treatments including anti-CD38 antibody and lenalidomide therapy [ID6591]
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Epcoritamab for treating relapsed or refractory diffuse large B-cell lymphoma after first-line systemic treatment [ID6463]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Epcoritamab for treating relapsed or refractory follicular lymphoma after 2 or more systemic treatments [ID6338]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
25 February 2026
Epcoritamab + R-CHOP for Diffuse large B-cell lymphoma (DLBCL) [TSID12334]
Status:
Topic prioritisation
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Epcoritamab + R-CHOP for Diffuse large B-cell lymphoma [ID6701]
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Epcoritamab with rituximab and lenalidomide for treating relapsed or refractory follicular lymphoma after 1 or more systemic treatments [ID6586]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
3 September 2026
Gilteritinib + daunorubicin + cytarabine for Acute myeloid leukaemia (AML) [TSID12331]
Status:
Topic prioritisation
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Gilteritinib with standard chemotherapy for newly diagnosed FLT3-mutation-positive acute myeloid leukaemia when intensive chemotherapy is suitable [ID6704]
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Gilteritinib with standard chemotherapy for newly diagnosed FLT3-mutation-positive acute myeloid leukaemia when intensive chemotherapy is suitable [TSID12331]
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Glofitamab with gemcitabine and oxaliplatin for treating relapsed or refractory diffuse large B-cell lymphoma (TA1113)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
3 December 2025
Histamine dihydrochloride with interleukin-2 for maintenance treatment of acute myeloid leukaemia [ID1627]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Ibrutinib for treating relapsed or refractory follicular lymphoma [ID1251]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Ibrutinib with R-CHOP for untreated mantle cell lymphoma when an autologous stem cell transplant is suitable [ID6596]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Isatuximab in combination for maintenance treatment of newly diagnosed multiple myeloma after an autologous stem cell transplant [ID6639]
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Isatuximab in combination for untreated multiple myeloma when a stem cell transplant is unsuitable (TA1098)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
24 September 2025
Isatuximab with pomalidomide and dexamethasone for treating relapsed and refractory multiple myeloma [review of TA658] [ID4067]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
11 March 2026
Linvoseltamab for treating relapsed or refractory multiple myeloma after 3 or more treatments [ID6609]
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Lisocabtagene maraleucel for treating relapsed or refractory large B-cell lymphoma after 2 or more systemic treatments (review of TA987) [ID6619]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Lisocabtagene maraleucel for treating relapsed or refractory low-grade B-cell follicular lymphoma after 1 or more treatments [ID6564]
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Lisocabtagene maraleucel for treating relapsed or refractory mantle cell lymphoma [ID6695]
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Loncastuximab Tesirine + Rituximab for Diffuse large B-cell lymphoma [ID6686]
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Luspatercept for Anaemia due to myelodysplastic syndromes [TSID12310]
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Luspatercept for treating anaemia caused by myelofibrosis [ID6697]
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Mezigdomide with dexamethasone and carfilzomib for treating relapsed or refractory multiple myeloma after at least 1 line of treatment [ID6513]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Mosunetuzumab with lenalidomide for treating relapsed or refractory follicular lymphoma after 1 or more systemic treatments [ID6655]
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Nivolumab + Brentuximab vedotin for Hodgkin lymphoma [ID6691]
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Nivolumab in combination for untreated advanced classical Hodgkin lymphoma in people 12 years and over [ID6690]
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Obecabtagene autoleucel for treating relapsed or refractory B-cell precursor acute lymphoblastic leukaemia (TA1116)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
11 December 2025
Odronextamab for treating relapsed or refractory follicular lymphoma [TSID12236]
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Peginterferon alfa-2a for treating polycythaemia vera or essential thrombocythaemia [TSID12325]
Status:
Topic prioritisation
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Pirtobrutinib for treating chronic lymphocytic leukaemia or small lymphocytic lymphoma after 1 or more BTK inhibitors [ID6269]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Pirtobrutinib for treating relapsed or refractory mantle cell lymphoma untreated with a BTK inhibitor [ID6493]
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Pirtobrutinib for untreated chronic lymphocytic leukaemia or small lymphocytic lymphoma [ID6397]
Status:
In development | In consultation
Programme:
Technology appraisal guidance
Consultation end date:
11 February 2026
Expected publication date:
TBC
Pirtobrutinib with venetoclax and rituximab for previously treated chronic lymphocytic leukaemia or small lymphocytic lymphoma [ID6566]
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Ponatinib for treating recurrent or refractory chronic myeloid leukaemia in people 1 to 17 years when another tyrosine kinase inhibitor is unsuitable [TSID12041]
Status:
Topic prioritisation
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Prognostic tests for multiple myeloma
Status:
Awaiting development
Programme:
HealthTech guidance
Expected publication date:
TBC
Resminostat for maintenance treatment of advanced mycosis fungoides or Sezary syndrome [ID6478]
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Rusfertide for treating polycythaemia vera in people having phlebotomy [ID6709]
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Selinexor + pomalidomide + dexamethasone for Multiple myeloma [TSID12333]
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Selinexor with ruxolitinib for treating splenomegaly or symptoms in myelofibrosis untreated with a JAK inhibitor [TSID12341]
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Sonrotoclax for treating relapsed or refractory mantle cell lymphoma after an anti-CD20 treatment and a BTK inhibitor [ID6654]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Surovatamig for treating relapsed or refractory B-cell acute lymphoblastic leukaemia after 2 or more lines of treatment in people 12 years and over [ID6630]
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Surovatamig for treating relapsed or refractory diffuse large B-cell lymphoma after 2 or more lines of treatment [ID6631]
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Suspected Cancer: recognition and referral (update)
Status:
In development
Programme:
NICE guideline
Expected publication date:
25 March 2026
Tafasitamab with lenalidomide and R-CHOP for untreated high-intermediate-risk or high-risk diffuse large B-cell lymphoma [ID6568]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
10 June 2027
Tafasitamab with lenalidomide and rituximab for treating relapsed or refractory follicular lymphoma after 1 or more systemic treatments ID6413
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
15 July 2026
Talquetamab for treating relapsed and refractory multiple myeloma after 3 or more treatments (TA1114)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
3 December 2025
Talquetamab with daratumumab for treating relapsed or refractory multiple myeloma after 1 or more lines of treatment including a proteasome inhibitor and lenalidomide [ID6625]
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Talquetamab with pomalidomide or teclistamab for treating relapsed or refractory multiple myeloma after 1 or more treatments including an anti-CD38 antibody and lenalidomide [ID6629]
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Teclistamab for treating relapsed or refractory multiple myeloma after 1 or more treatments including an anti-CD38 antibody and lenalidomide [ID6628]
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Transarterial radio embolisation for osteosarcoma liver metastases
Status:
Topic prioritisation
Programme:
Interventional procedures guidance
Expected publication date:
TBC
Venetoclax with azacitidine for treating acute myeloid leukaemia before and after an allogeneic stem cell transplant [ID6468]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Venetoclax with azacitidine for untreated high-risk myelodysplastic syndromes [ID6314]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Venetoclax with ibrutinib for treating relapsed mantle cell lymphoma [ID3879]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Venetoclax with obinutuzumab for untreated chronic lymphocytic leukaemia (TA1119)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
7 January 2026
Zanubrutinib with rituximab for untreated mantle cell lymphoma when a stem cell transplant is unsuitable [ID6641]
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC